Back to Search Start Over

Stroke incidence and cognitive outcomes of intracranial atherosclerotic stenosis: study protocol for a multicenter, prospective, observational cohort study

Authors :
Qianqian, Si
Yuming, Teng
Caiyan, Liu
Weizhuang, Yuan
Xiaoyuan, Fan
Xiaoqian, Zhang
Zongmuyu, Zhang
Mingli, Li
Qing, Liu
Peng, Wang
Zhongrui, Yan
Bo, Wu
Qiang, Liu
Hangjuan, Li
Yan, Ji
Yuncai, Ran
Bo, Song
Shiguang, Zhu
Hongyan, Li
Jingxia, Guan
Manli, Zhao
Yonggang, Hao
Pengfei, Wang
Hong, Bian
Ningfen, Wang
Yulin, Wang
Yuning, Pan
Hongwei, An
Rong, Guo
Cong, Han
Junshi, Zhang
Hebo, Wang
Yong, You
Hongquan, Jiang
Zifan, Liu
Jingli, Liu
Dingbo, Tao
Xiangyu, Piao
Jiangtao, Zhang
Pei, Wang
Shen, Yang
Zhou, Liu
Xiue, Wei
Kai, Han
Zhimin, Shi
Aihua, Liu
Zuowen, Zhang
Chunye, Ma
Baichen, Wang
Gejuan, Zhang
Chengguang, Song
Guilian, Zhang
Xiao, Yang
Bing, Chen
Baoquan, Lu
Beilei, Chen
Meng, Zuo
Kun, Han
Xiaodan, Zhang
Wenfeng, Cao
Lingfeng, Wu
Qi, Li
Xiaokun, Geng
Junshan, Zhou
Mengfei, Zhong
Minghua, Wang
Yangmei, Chen
Jiachun, Liu
Tingrui, Wang
Youqing, Deng
Weihai, Xu
Source :
Annals of Translational Medicine. 10:909-909
Publication Year :
2022
Publisher :
AME Publishing Company, 2022.

Abstract

Intracranial atherosclerotic stenosis (ICAS) is one of the leading causes of stroke worldwide. Current diagnostic evaluations and treatments remain insufficient to assess the vulnerability of intracranial plaques and reduce the recurrence of stroke in symptomatic ICAS. On the other hand, asymptomatic ICAS is associated with an increased risk of cognitive impairment. The pathogenesis of ICAS related cognitive decline is largely unknown. The aim of SICO-ICAS study (stroke incidence and cognitive outcomes of ICAS) is to elucidate the pathophysiology of stroke and cognitive impairment in ICAS population, comprehensively evaluating the complex interactions among life-course exposure, genomic variation, vascular risk factors, cerebrovascular burden and coexisting neurodegeneration.SICO-ICAS is a multicenter, prospective, observational cohort study. We aim to recruit 3,000 patients with symptomatic or asymptomatic ICAS (50% or occlusion) who will be followed up for ≥12 months. All participants will undergo pre-designed magnetic resonance imaging packages, blood biomarkers testing, as well as detailed cognitive domains assessment. All participants will undergo clinical visits every 6 months and telephone interviews every 3 months. The primary outcome measurement is ischemic stroke or cognitive impairment within 12 months after enrollment.This study will establish a large prospective ICAS cohort, hopefully discover new biomarkers associated with vulnerable intracranial plaques, identify subjects at high risk for incident ischemic stroke or cognitive impairment, and eventually propose a precise diagnostic and treatment strategy for ICAS population.Chinese Clinical Trials Register ChiCTR2200061938.

Subjects

Subjects :
General Medicine

Details

ISSN :
23055847 and 23055839
Volume :
10
Database :
OpenAIRE
Journal :
Annals of Translational Medicine
Accession number :
edsair.doi.dedup.....193b1dd54b910117a8094da29c89954e
Full Text :
https://doi.org/10.21037/atm-22-3570